Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | ONCR-177 |
Trade Name | |
Synonyms | ONCR177|ONCR 177 |
Drug Descriptions |
ONCR-177 is an oncolytic herpes simplex virus (HSV) engineered to express PD-1 and CTLA-4 antagonists, IL-12, CCL4, and the extracellular domain of FLT3LG, and to contain a microRNA-binding cassette that potentially allows selective HSV replication in tumor cells, which may enhance anti-tumor immune response and induce tumor cell killing (Cancer Res 2019;79(13 Suppl):Abstract nr 1455). |
DrugClasses | CTLA4 Inhibitor 4 |
CAS Registry Number | NA |
NCIT ID | C171540 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
ONCR-177 | ONCR-177 | 0 | 1 |
ONCR-177 + Pembrolizumab | ONCR-177 Pembrolizumab | 0 | 1 |